Highlights Arvinas, Inc.

Equities

ARVN

US04335A1051

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
31.44 ^USD	-1.60%		-4.20%	-23.62%

08/05	Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating	MT
07/05	Arvinas Shares Up After Q1 Net Loss Narrows	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arvinas Shares Up After Q1 Net Loss Narrows	07/05	MT
Earnings Flash (ARVN) ARVINAS Reports Q1 Revenue $25.3M	07/05	MT
Arvinas, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	12/04	MT
Novartis: licensing agreement in prostate cancer	11/04	CF
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	11/04	MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact	11/04	DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion	11/04	RE
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer	11/04	CI
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue	27/02	MT
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
Arvinas, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02	CI
North American Morning Briefing : S&P 500 Seen -2-	16/02	DJ
Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy	06/02	CI
Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program	06/12	CI
Earnings Flash (ARVN) ARVINAS Posts Q3 Revenue $34.6M	07/11	MT
Arvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide	22/23/22	CI
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023	16/23/16	CI
Earnings Flash (ARVN) ARVINAS Posts Q2 Revenue $54.5M	08/23/08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arvinas, Inc.

Equities

ARVN

US04335A1051

Highlights

Filters